{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:47:33Z","timestamp":1783655253515,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["NCT05634785"],"award-info":[{"award-number":["NCT05634785"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijgc.2025.101670","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T03:06:04Z","timestamp":1738119964000},"page":"101670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Controversies in malignant ovarian germ cell tumors"],"prefix":"10.1016","volume":"35","author":[{"given":"Michael J.","family":"Seckl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Ghorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijgc.2025.101670_bib1","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/01.AOG.0000216004.22588.ce","article-title":"Incidence and survival rates for female malignant germ cell tumors","volume":"107","author":"Smith","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib2","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/ijc.32810","article-title":"Testicular cancer incidence predictions in Europe 2010\u20132035: a rising burden despite population ageing","volume":"147","author":"Znaor","year":"2020","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101670_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41568-019-0178-9","article-title":"Human germ cell tumors from a developmental perspective","volume":"19","author":"Oosterhuis","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101670_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/joim.13778","article-title":"Malignant ovarian and testicular germ cell tumors: common characteristics but different prognoses","volume":"295","author":"Sk\u00f6ld","year":"2024","journal-title":"J Intern Med"},{"issue":"30","key":"10.1016\/j.ijgc.2025.101670_bib5","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1200\/JCO.2006.06.2489","article-title":"Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment","volume":"24","author":"Murugaesu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2014.59.4325","article-title":"High-dose chemotherapy for recurrent ovarian germ cell tumors","volume":"33","author":"Reddy Ammakkanavar","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2020.05.007","article-title":"Contemporary management of ovarian germ cell tumors and remaining controversies","volume":"158","author":"Veneris","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumors of the urinary system and male genital organs-part A: renal, penile, and testicular tumors","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101670_bib9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41374-020-0468-6","article-title":"Lack of genetic homozygosity in prepubertal teratomas: divergent pathogenesis distinct from that of teratomas in adolescents","volume":"100","author":"Snir","year":"2020","journal-title":"Lab Investig"},{"key":"10.1016\/j.ijgc.2025.101670_bib10","series-title":"Rare Tumors in Children and Adolescents","first-page":"301","article-title":"Gonadal and extragonadal germ cell tumors, sex cord stromal and rare gonadal tumors","author":"Schneider","year":"2022"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0165-4608(95)00067-Y","article-title":"Chromosome 12 abnormalities in malignant ovarian germ cell tumors","volume":"82","author":"Rodriguez","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101670_bib12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/modpathol.3800596","article-title":"Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements","volume":"19","author":"Poulos","year":"2006","journal-title":"Mod Pathol."},{"issue":"6","key":"10.1016\/j.ijgc.2025.101670_bib13","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.0.CO;2-V","article-title":"Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors","volume":"85","author":"Ross","year":"1999","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/gcc.20237","article-title":"IGF2\/H19 imprinting analysis of human germ cell tumors (GCTs) using the methylation-sensitive single-nucleotide primer extension method reflects the origin of GCTs in different stages of primordial germ cell development","volume":"44","author":"Sievers","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101670_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1242\/dev.101428","article-title":"Genomic imprinting in development, growth, behavior, and stem cells","volume":"141","author":"Plasschaert","year":"2014","journal-title":"Development"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/cncr.29732","article-title":"Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative","volume":"122","author":"Pashankar","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijgc.2025.101670_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102453","article-title":"Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective","volume":"69","author":"Pashankar","year":"2024","journal-title":"EClinicalmedicine"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101670_bib18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/bjc.1996.173","article-title":"Familial testicular cancer in Norway and southern Sweden","volume":"73","author":"Heimdal","year":"1996","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canep.2009.04.015","article-title":"A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome","volume":"33","author":"Giambartolomei","year":"2009","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/gcc.20951","article-title":"Associations between variants in KITLG, SPRY4, BAK1, and DMRT1 and pediatric germ cell tumors","volume":"51","author":"Poynter","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.beem.2009.10.002","article-title":"Gonadal tumors and DSD","volume":"24","author":"Looijenga","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1210\/er.2012-1045","article-title":"Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis","volume":"34","author":"Kraggerud","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ijgc.2025.101670_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1476-4598-6-12","article-title":"Ovarian dysgerminomas are characterized by frequent KIT mutations and abundant expression of pluripotency markers","volume":"6","author":"Hoei-Hansen","year":"2007","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2018.08.013","article-title":"The genetic landscape of 87 ovarian germ cell tumors","volume":"151","author":"Van Nieuwenhuysen","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"7631","key":"10.1016\/j.ijgc.2025.101670_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature20596","article-title":"Genomic evolution and chemoresistance in germ-cell tumors","volume":"540","author":"Taylor-Weiner","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib26","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41467-023-38378-9","article-title":"Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence","volume":"14","author":"Xu","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2350\/08-05-0097.1","article-title":"Activation of Wnt\/beta-catenin signaling in distinct histologic subtypes of human germ cell tumors","volume":"9","author":"Fritsch","year":"2006","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.ijgc.2025.101670_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.critrevonc.2019.09.005","article-title":"Targeted treatment approaches in refractory germ cell tumors","volume":"143","author":"Galvez-Carvajal","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.coc.0000195086.47548.ef","article-title":"Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT","volume":"29","author":"Einhorn","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101670_bib30","first-page":"2648","article-title":"Phase II multicenter study of imatinib in patients with chemorefractory germ cell tumors that express c-kit","volume":"67","author":"Piulats","year":"2007","journal-title":"Cancer Res."},{"issue":"4C","key":"10.1016\/j.ijgc.2025.101670_bib31","first-page":"2317","article-title":"Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma","volume":"28","author":"Pectasides","year":"2008","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00432-018-2752-z","article-title":"Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group","volume":"145","author":"Fenner","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101670_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00004347-199410000-00001","article-title":"The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading","volume":"13","author":"O\u2019Connor","year":"1994","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2025.101670_bib34","series-title":"WHO Classification of Tumors Series","year":"2020"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5858\/arpa.2012-0547-RA","article-title":"Germ cell tumors of the ovary: an update","volume":"138","author":"Nogales","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004347-198709000-00002","article-title":"Relation of ovarian dermoid cysts and immature teratomas: an analysis of 350 cases of immature teratoma and 10 cases of dermoid cyst with microscopic foci of immature tissue","volume":"6","author":"Yanai-Inbar","year":"1987","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2025.101670_bib37","series-title":"TNM Supplement: A Commentary on Uniform Use","author":"Hoboken","year":"2019"},{"key":"10.1016\/j.ijgc.2025.101670_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2020.06.033","article-title":"Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis","volume":"137","author":"Bergamini","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101670_bib39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/his.13426","article-title":"Germ cell tumor growth patterns originating from clear cell carcinomas of the ovary and endometrium: a comparative immunohistochemical study favouring their origin from somatic stem cells","volume":"72","author":"Nogales","year":"2018","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101670_bib40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/his.13021","article-title":"Yolk sac tumors of the female genital tract in older adults derive commonly from somatic epithelial neoplasms: somatically derived yolk sac tumors","volume":"69","author":"McNamee","year":"2016","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101670_bib41","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1038\/s41379-020-0548-6","article-title":"Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation","volume":"33","author":"Skala","year":"2020","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101670_bib42","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/s41379-019-0341-6","article-title":"Endometrial tumors with yolk sac tumor-like morphologic patterns or immunophenotypes: an expanded appraisal","volume":"32","author":"Fadare","year":"2019","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group","volume":"15","year":"1997","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ijgc.2025.101670_bib44","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101670_bib45","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.ejca.2014.03.288","article-title":"Prognostic factors in malignant ovarian germ cell tumors (The Surveillance, Epidemiology and End Results experience 1978\u20132010)","volume":"50","author":"Solheim","year":"2014","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101670_bib46","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000534674","article-title":"Clinicopathological features and survival trends of non-epithelial ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database","volume":"46","author":"Zhang","year":"2023","journal-title":"Oncol Res Treat"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ygyno.2004.11.027","article-title":"Outcome and prognostic factors in ovarian germ cell malignancies","volume":"96","author":"Lai","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101670_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ygyno.2022.12.022","article-title":"Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management","volume":"170","author":"Liu","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101670_bib49","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1136\/ijgc-2024-005489","article-title":"Predicting outcomes in malignant ovarian germ cell tumors using the modified International Germ Cell Cancer Collaborative Group classification system","volume":"34","author":"Zhang","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.101670_bib50","series-title":"Malignant Ovarian Germ Cell Tumor Guidelines. NCCN.org","article-title":"NCCN guidelines: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer","year":"2024"},{"issue":"suppl 4","key":"10.1016\/j.ijgc.2025.101670_bib51","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","article-title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2014.09.006","article-title":"Laparoscopic staging of apparent early-stage ovarian cancer: results of a large, retrospective, multi-institutional series","volume":"135","author":"Gallotta","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101670_bib53","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1245\/s10434-011-2138-9","article-title":"Laparoscopic staging of early ovarian cancer: results of a multi-institutional cohort study","volume":"19","author":"Ghezzi","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijgc.2025.101670_bib54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejogrb.2013.10.023","article-title":"Surgical management of non-epithelial ovarian malignancies: advantages and limitations of laparoscopy","volume":"172","author":"Gremeau","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101670_bib55","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/IGC.0b013e3182236582","article-title":"Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study","volume":"21","author":"Mangili","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib56","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ijgc-2018-000013","article-title":"Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors","volume":"29","author":"Nasioudis","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/IGC.0b013e318272e754","article-title":"Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes","volume":"23","author":"Shim","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101670_bib58","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jpedsurg.2024.02.017","article-title":"Impact of surgical timing (primary, delayed, or second look) on surgical morbidity and outcomes in malignant germ cell tumor of the ovary in children","volume":"59","author":"Qureshi","year":"2024","journal-title":"J Pediatr Surg"},{"issue":"18","key":"10.1016\/j.ijgc.2025.101670_bib59","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.3390\/cancers15184470","article-title":"Systematic review of the survival outcomes of neoadjuvant chemotherapy in women with malignant ovarian germ cell tumors","volume":"15","author":"Sakaguchi-Mukaida","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib60","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0959-8049(99)00317-2","article-title":"Non-seminomatous ovarian germ cell tumors in children","volume":"36","author":"Baranzelli","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.101670_bib61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.critrevonc.2017.11.015","article-title":"Long-term toxicity of the treatment for germ cell-cancer. A review","volume":"121","author":"Maroto","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib62","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ygyno.2017.02.006","article-title":"Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer","volume":"145","author":"Skalleberg","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib63","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.1997.15.2.620","article-title":"Surveillance policy for stage I ovarian germ cell tumors","volume":"15","author":"Dark","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ijgc-00009577-200801000-00007","article-title":"A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites","volume":"18","author":"Patterson","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101670_bib65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdw563","article-title":"The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study","volume":"28","author":"Mangili","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101670_bib66","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1245\/s10434-016-5234-z","article-title":"Significance of the complete surgical staging of Stage I malignant ovarian germ cell tumors","volume":"23","author":"Park","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib67","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ygyno.2020.06.491","article-title":"Need for risk-adapted therapy for malignant ovarian germ cell tumors: a large multicenter analysis of germ cell tumors\u2019 patients from French TMRG network","volume":"158","author":"Derquin","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101670_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/COC.0000000000000805","article-title":"Surveillance only for high-risk FIGO stage IA\/IB malignant ovarian germ cell tumors: results from a national cancer database","volume":"44","author":"Nasioudis","year":"2021","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101670_bib69","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/ijgc-2021-002575","article-title":"Surveillance alone in stage I malignant ovarian germ cell tumors: a MITO (Multicenter Italian Trials in Ovarian cancer) prospective observational study","volume":"31","author":"Mangili","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101670_bib70","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/s12885-019-5968-7","article-title":"Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumors (GCT) and trophoblastic neoplasia (TN)","volume":"19","author":"Chan Wah Hak","year":"2019","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.ijgc.2025.101670_bib71","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2007.10.8738","article-title":"Management of ovarian germ cell tumors","volume":"25","author":"Gershenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101670_bib72","series-title":"50 Big Debates in Gynecologic Oncology","first-page":"132","article-title":"What is the optimal chemotherapy regimen for ovarian germ-cell tumors? Bleomycin, etoposide and cisplatinum (BEP) versus other","author":"Seckl","year":"2023"},{"key":"10.1016\/j.ijgc.2025.101670_bib73","series-title":"StatPearls","article-title":"Alpha-fetoprotein analysis","author":"Adigun","year":"2024"},{"key":"10.1016\/j.ijgc.2025.101670_bib74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2020.08.031","article-title":"Single-agent carboplatin AUC10 in metastatic seminoma: a multi-center UK study of 216 patients","volume":"164","author":"Alifrangis","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2025.101670_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1271647","article-title":"Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy","volume":"13","author":"Wood","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101670_bib76","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1008279222625","article-title":"Treatment of men with metastatic non-seminomatous germ cell tumors with cyclical POMB\/ACE chemotherapy","volume":"8","author":"Bower","year":"1997","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2025.101670_bib77","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.23.02542","article-title":"Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: long-term follow-up and outcomes for favorable- and unfavorable-risk disease","volume":"42","author":"Gleeson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101670_bib78","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/sj.bjc.6601664","article-title":"Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumors","volume":"90","author":"McNeish","year":"2004","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101670_bib79","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s00345-022-03959-8","article-title":"First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : a comprehensive review compiled by the German Testicular Cancer Study Group","volume":"40","author":"Pfister","year":"2022","journal-title":"World J Urol."},{"issue":"5","key":"10.1016\/j.ijgc.2025.101670_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103449","article-title":"Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis","volume":"9","author":"Seidel","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101670_bib81","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/annonc\/mdx259","article-title":"Salvage high-dose chemotherapy in female patients with relapsed\/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"28","author":"De Giorgi","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101670_bib82","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/cancers16071379","article-title":"Advancing GCT management: a review of miR-371a-3p and other miRNAs in comparison to traditional serum tumor markers","volume":"16","author":"Seales","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijgc.2025.101670_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118610","article-title":"Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: potential treatment options against Testicular Germ Cell Tumors","volume":"14","author":"Schepisi","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101670_bib84","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/cncr.29213","article-title":"Phase 2 trial of the cyclin-dependent kinase 4\/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101670_bib85","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.immuni.2023.09.004","article-title":"Cancer cell-intrinsic mechanisms driving acquired immune tolerance","volume":"56","author":"Ghorani","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ijgc.2025.101670_bib86","article-title":"Treatment of recurrent ovarian germ cell tumors: is there a role for immune checkpoint inhibitors?","volume":"56","author":"Bernard","year":"2024","journal-title":"Gynecol Oncol Rep"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101670_bib87","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101670_bib88","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/ijgc-2023-004699","article-title":"Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study","volume":"33","author":"Bergamini","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101670_bib89","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/ijgc-2020-001775","article-title":"Fertility preservation in rare ovarian tumors","volume":"31","author":"Chelariu-Raicu","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.101670_bib90","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ygyno.2023.11.023","article-title":"Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs","volume":"181","author":"Vasta","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2025.101670_bib91","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.3390\/jcm13154513","article-title":"Exploring the frontiers of ovarian tissue cryopreservation: a review","volume":"13","author":"Ramirez","year":"2024","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.ijgc.2025.101670_bib92","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","article-title":"No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial","volume":"34","author":"Demeestere","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101670_bib93","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2020.03.030","article-title":"Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumors (KGOG 3048R)","volume":"133","author":"Choi","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101670_bib94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clgc.2023.03.018","article-title":"Late relapse of germ cell tumors after prior chemotherapy or surgery-only","volume":"21","author":"Richardson","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101670_bib95","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.hoc.2024.08.019","article-title":"Future directions for gestational trophoblastic disease","volume":"38","author":"Ghorani","year":"2024","journal-title":"Hematol Oncol Clin North Am."}],"updated-by":[{"DOI":"10.1016\/j.ijgc.2025.101954","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:39:23Z","timestamp":1772329163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1048891X25001951"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101670","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in malignant ovarian germ cell tumors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101670"}}